cytarabine and 7-hydroxystaurosporine

cytarabine has been researched along with 7-hydroxystaurosporine in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (14.29)	18.2507
2000's	5 (71.43)	29.6817
2010's	1 (14.29)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bartimole, TM; Dent, P; Freemerman, AJ; Grant, S; Jarvis, WD; Kramer, LB; Krystal, G; Vrana, JA; Wang, S	1
Boise, LH; Dent, P; Grant, S; Tang, L	1
Grant, S; Wang, S; Wang, Z	1
Cao, CX; Pommier, Y; Shao, RG	1
Azuma, A; Chubb, S; Guo, Y; Hittelman, W; Huang, P; Jiang, Y; Li, Y; Liu, X; Matsuda, A; Plunkett, W	1
Andreeff, M; Cortes, J; Du, M; Estrov, Z; Gandhi, V; Plunkett, W; Sampath, D; Shi, Z	1
Chung, I; Eastman, A; Garner, KM; Montano, R; Parry, D	1

Trials

1 trial(s) available for cytarabine and 7-hydroxystaurosporine

Article	Year
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood, 2006, Mar-15, Volume: 107, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Cell Cycle; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cytarabine; DNA Damage; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid, Acute; Middle Aged; Oncogene Protein v-akt; Pharmacokinetics; Phosphorylation; Pilot Projects; Protein Kinases; Salvage Therapy; Staurosporine; Tumor Cells, Cultured	2006

Article

Year

Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.

Blood, 2006, Mar-15, Volume: 107, Issue:6

Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Cell Cycle; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cytarabine; DNA Damage; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid, Acute; Middle Aged; Oncogene Protein v-akt; Pharmacokinetics; Phosphorylation; Pilot Projects; Protein Kinases; Salvage Therapy; Staurosporine; Tumor Cells, Cultured

2006

Other Studies

6 other study(ies) available for cytarabine and 7-hydroxystaurosporine

Article	Year
Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Molecular pharmacology, 1997, Volume: 52, Issue:6 Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Bryostatins; Cytarabine; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Endopeptidases; Enzyme Inhibitors; HL-60 Cells; Humans; Lactones; Macrolides; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Staurosporine	1997
Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). Biochemical pharmacology, 2000, Nov-15, Volume: 60, Issue:10 Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cytarabine; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia; Mitochondria; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Staurosporine; U937 Cells	2000
Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms. Molecular pharmacology, 2003, Volume: 63, Issue:1 Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bryostatins; Carrier Proteins; Caspases; Cytarabine; Cytochrome c Group; Drug Synergism; Enzyme Activation; Gene Deletion; HL-60 Cells; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Lactones; Leukemia, Myeloid; Macrolides; Maleimides; Mitochondrial Proteins; Mutation; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Receptors, Tumor Necrosis Factor; Staurosporine; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; U937 Cells	2003
Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells. Acta pharmacologica Sinica, 2004, Volume: 25, Issue:6 Topics: Antineoplastic Agents; CDC2-CDC28 Kinases; cdc25 Phosphatases; Cell Cycle Proteins; Checkpoint Kinase 1; Cyclin A; Cyclin B; Cyclin-Dependent Kinase 2; Cytarabine; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; G2 Phase; HT29 Cells; Humans; Protein Kinases; S Phase; Staurosporine	2004
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer research, 2005, Aug-01, Volume: 65, Issue:15 Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Chromosome Aberrations; Cytarabine; DNA Damage; Drug Interactions; G2 Phase; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Mitosis; Protein Kinases; Signal Transduction; Staurosporine	2005
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Molecular cancer therapeutics, 2012, Volume: 11, Issue:2 Topics: Antimetabolites; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Hydroxyurea; Irinotecan; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Staurosporine	2012